The aim of this Research Topic is to highlight the nature and the challenges of Genitourinary (GU) oncology practice in Low-to-Middle income countries (LMIC) across the globe. As there is an exigent need to address the status of GU oncology practice in this part of the world, where half of the world population reside. The articles in this Research Topic will help physicians, researchers, as well as stakeholders in the field to direct their efforts to improve GU oncology globally.
We welcome articles covering the following topics:
1: Incidence and stage at presentation of GU cancers , and GU cancer registries in LMIC.
2: Research, clinical trials, databases, and funding opportunities for GU cancers in LMIC.
3: Post-graduate training opportunities in GU oncology for different subspecialties in LMIC.
4: GU cancers survivorship programs in LMIC.
5: Quality of life indicators for GU cancer in LMIC.
6: Access to radiotherapy in LMIC.
7: Access to standard of care chemotherapy and immunotherapy and novel treatments for GU cancers in LMIC.
8: Access to surgery and minimally invasive surgery for GU cancers in LMIC.
The Topic Editors Ibrahim Abu Ghaida receives financial support from AstraZeneca. The Topic Editor, Mohammed Shahait, receives financial support from Astellas & MDS. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
The aim of this Research Topic is to highlight the nature and the challenges of Genitourinary (GU) oncology practice in Low-to-Middle income countries (LMIC) across the globe. As there is an exigent need to address the status of GU oncology practice in this part of the world, where half of the world population reside. The articles in this Research Topic will help physicians, researchers, as well as stakeholders in the field to direct their efforts to improve GU oncology globally.
We welcome articles covering the following topics:
1: Incidence and stage at presentation of GU cancers , and GU cancer registries in LMIC.
2: Research, clinical trials, databases, and funding opportunities for GU cancers in LMIC.
3: Post-graduate training opportunities in GU oncology for different subspecialties in LMIC.
4: GU cancers survivorship programs in LMIC.
5: Quality of life indicators for GU cancer in LMIC.
6: Access to radiotherapy in LMIC.
7: Access to standard of care chemotherapy and immunotherapy and novel treatments for GU cancers in LMIC.
8: Access to surgery and minimally invasive surgery for GU cancers in LMIC.
The Topic Editors Ibrahim Abu Ghaida receives financial support from AstraZeneca. The Topic Editor, Mohammed Shahait, receives financial support from Astellas & MDS. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
